LONG‐TERM OUTCOME IN ADULTS WITH OBSESSIVE‐COMPULSIVE DISORDER

Obsessive‐compulsive disorder (OCD) is a chronic condition that often produces lifelong morbidity, but few studies have examined long‐term outcome (greater than 5 years) in adult patients. Available studies suggest that 32–74% of adult OCD patients will experience clinical improvement over the long term. However, these studies were conducted before validated OCD rating scales were established and the development of evidence‐based treatments for OCD.

[1]  M. Hamilton.  The assessment of anxiety states by rating. , 1959, The British journal of medical psychology.

[2]  D. Rosenberg,et al.  Brain anatomy and chemistry may predict treatment response in paediatric obsessive--compulsive disorder. , 2001, The international journal of neuropsychopharmacology.

[3]  S. Whiteside,et al.  A magnetic resonance spectroscopy investigation of obsessive–compulsive disorder and anxiety , 2006, Psychiatry Research: Neuroimaging.

[4]  H. Delkeskamp.  LANGSTRECKEN‐KATAMNSESEN VON ZWANGSNEUROSEN 1 , 1965 .

[5]  D. W. Goodwin,et al.  Follow-up studies in obsessional neurosis. , 1969, Archives of general psychiatry.

[6]  S. E. Stewart,et al.  Long‐term outcome of pediatric obsessive–compulsive disorder: a meta‐analysis and qualitative review of the literature , 2004, Acta psychiatrica Scandinavica.

[7]  W. Goodman,et al.  The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. , 1989, Archives of general psychiatry.

[8]  S. Sorenson,et al.  The epidemiology of obsessive-compulsive disorder in five US communities. , 1988, Archives of general psychiatry.

[9]  T. Hendler,et al.  Epidemiology of obsessive-compulsive disorder: a world view. , 1997, The Journal of clinical psychiatry.

[10]  S. Rauch,et al.  Invasive Circuitry-Based Neurotherapeutics: Stereotactic Ablation and Deep Brain Stimulation for OCD , 2010, Neuropsychopharmacology.

[11]  J. Kennedy,et al.  Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder. , 2006, Archives of general psychiatry.

[12]  L. Koran,et al.  Quality of life for patients with obsessive-compulsive disorder. , 1996, The American journal of psychiatry.

[13]  Abraham Weizman,et al.  Memantine for treatment-resistant OCD. , 2005, The American journal of psychiatry.

[14]  G. Berríos,et al.  Obsessive-Compulsive Disorders in Cambridgeshire , 1989, British Journal of Psychiatry.

[15]  E. Hollander,et al.  Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. , 2011, The Journal of clinical psychiatry.

[16]  S. Rasmussen,et al.  A 2-year prospective follow-up study of the course of obsessive-compulsive disorder. , 2010, The Journal of clinical psychiatry.

[17]  E. Rudin.  [On the problem of compulsive disease with special reference to its hereditary relations]. , 1953, Archiv fur Psychiatrie und Nervenkrankheiten, vereinigt mit Zeitschrift fur die gesamte Neurologie und Psychiatrie.

[18]  S. Rasmussen,et al.  Predictors of course in obsessive compulsive disorder , 1999, Psychiatry Research.

[19]  M. Biondi,et al.  Memantine augmentation for refractory obsessive–compulsive disorder , 2006, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[20]  D. Dickel,et al.  Association testing of the positional and functional candidate gene SLC1A1/EAAC1 in early-onset obsessive-compulsive disorder. , 2006, Archives of general psychiatry.

[21]  C. Pittenger,et al.  Meta-Analysis of the Symptom Structure of Obsessive-Compulsive Disorder , 2015 .

[22]  K. Chakrabarty,et al.  Glutamatergic Dysfunction in OCD , 2005, Neuropsychopharmacology.

[23]  M. Hamilton,et al.  Clinical syndromes in depressive states. , 1959, The Journal of mental science.

[24]  W. Goodman,et al.  The Yale-Brown Obsessive Compulsive Scale. II. Validity. , 1989, Archives of general psychiatry.

[25]  E. Hollander,et al.  Treatment non-response in OCD: methodological issues and operational definitions. , 2002, The international journal of neuropsychopharmacology.

[26]  W. Guy,et al.  Pretreatment status and its relationship to the length of drying-out period. , 1976, Psychopharmacology bulletin.

[27]  M. Jenike,et al.  Clomipramine in the treatment of patients with obsessive-compulsive disorder. The Clomipramine Collaborative Study Group. , 1991, Archives of general psychiatry.

[28]  J. Krystal,et al.  Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder. , 2010, Journal of affective disorders.

[29]  Ronald J. Faber,et al.  Compulsive buying: descriptive characteristics and psychiatric comorbidity. , 1994, The Journal of clinical psychiatry.

[30]  S. E. Stewart,et al.  Association of the SLC1A1 glutamate transporter gene and obsessive‐compulsive disorder , 2007, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[31]  J. Krystal,et al.  N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder , 2005, Psychopharmacology.

[32]  M. Keshavan,et al.  Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. , 2000, Journal of the American Academy of Child and Adolescent Psychiatry.

[33]  J. Krystal,et al.  Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder , 2011, NeuroRX.

[34]  M. Kozak,et al.  Treatment of obsessive—compulsive disorder with fluvoxamine: a multicentre, double‐blind, placebo‐controlled trial , 1996, International clinical psychopharmacology.

[35]  C. Muller.  [Preliminary report on the lengthy catamnesis of obsessive disorders]. , 1953, Der Nervenarzt.

[36]  D. Mathalon,et al.  Riluzole Augmentation in Treatment-Resistant Obsessive–Compulsive Disorder: An Open-Label Trial , 2005, Biological Psychiatry.

[37]  Dan J Stein,et al.  The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication , 2010, Molecular Psychiatry.

[38]  A. V. van Balkom,et al.  Cognitive therapy and exposure in vivo alone and in combination with fluvoxamine in obsessive-compulsive disorder: a 5-year follow-up. , 2005, The Journal of clinical psychiatry.

[39]  L. Price,et al.  A 40-year follow-up of patients with obsessive compulsive disorder , 2002, European Psychiatry.

[40]  E. Kringlen.  Obsessional Neurotics , 1965, British Journal of Psychiatry.

[41]  E. Spina,et al.  Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive–compulsive disorder: a double-blind, placebo-controlled study , 2012, Journal of psychopharmacology.

[42]  W. Goodman,et al.  Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo. , 1989, Archives of general psychiatry.

[43]  I. Skoog,et al.  A 40-year follow-up of patients with obsessive-compulsive disorder [see commetns]. , 1999, Archives of general psychiatry.

[44]  S. Rasmussen,et al.  The epidemiology and differential diagnosis of obsessive compulsive disorder. , 1992, The Journal of clinical psychiatry.

[45]  J. Sánchez-Meca,et al.  The Yale–Brown Obsessive Compulsive Scale , 2015, Assessment.

[46]  R. Kessler,et al.  Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. , 1994, Archives of general psychiatry.